1097 related articles for article (PubMed ID: 26468528)
1. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).
Lu F; Wikramasinghe P; Norseen J; Tsai K; Wang P; Showe L; Davuluri RV; Lieberman PM
Virol J; 2010 Oct; 7():262. PubMed ID: 20929547
[TBL] [Abstract][Full Text] [Related]
3. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
4. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
[TBL] [Abstract][Full Text] [Related]
7. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
J Virol; 2018 May; 92(9):. PubMed ID: 29467311
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells.
Wang L; Laing J; Yan B; Zhou H; Ke L; Wang C; Narita Y; Zhang Z; Olson MR; Afzali B; Zhao B; Kazemian M
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999023
[TBL] [Abstract][Full Text] [Related]
11. DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.
Yasuda A; Noguchi K; Minoshima M; Kashiwazaki G; Kanda T; Katayama K; Mitsuhashi J; Bando T; Sugiyama H; Sugimoto Y
Cancer Sci; 2011 Dec; 102(12):2221-30. PubMed ID: 21910783
[TBL] [Abstract][Full Text] [Related]
12. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.
Murakami M; Lan K; Subramanian C; Robertson ES
J Virol; 2005 Feb; 79(3):1559-68. PubMed ID: 15650182
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.
Messick TE; Smith GR; Soldan SS; McDonnell ME; Deakyne JS; Malecka KA; Tolvinski L; van den Heuvel APJ; Gu BW; Cassel JA; Tran DH; Wassermann BR; Zhang Y; Velvadapu V; Zartler ER; Busson P; Reitz AB; Lieberman PM
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842315
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
18. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.
Koganti S; Clark C; Zhi J; Li X; Chen EI; Chakrabortty S; Hill ER; Bhaduri-McIntosh S
J Virol; 2015 May; 89(9):5002-11. PubMed ID: 25717101
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-positive gastric cancer involves enhancer activation through activating transcription factor 3.
Asakawa Y; Okabe A; Fukuyo M; Li W; Ikeda E; Mano Y; Funata S; Namba H; Fujii T; Kita K; Matsusaka K; Kaneda A
Cancer Sci; 2020 May; 111(5):1818-1828. PubMed ID: 32119176
[TBL] [Abstract][Full Text] [Related]
20. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]